Business
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site networkNEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for
About this update from Psyence Biomedical Ltd.
[{"type":"image","alt":"Psyence Biomedical Ltd.","displaySize":"","headline":null,"caption":"Psyence Biomedical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/67bd17e4cdd6e19b07d34e625f8a453d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5PPb21XM3Df2Q9HxiIfXsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/globenewswire.com/67bd17e4cdd6e19b07d34e625f8a453d","width":300,"height":76}},"lazy":false},{"type":"text","content":"Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network","length":142,"tagName":"p"},{"type":"text","content":"NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.","length":448,"tagName":"p"},{"type":"text","content":"The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.","length":203,"tagName":"p"},{"type":"text","content":"NPX-5 is a GMP-compliant, nature-derived psilocybin candidate, developed as part of Psyence BioMed’s vertically integrated platform through its investment in PsyLabs. The program is designed to address a significant unmet need in palliative care by targeting the psychological distress associated with life-limiting illness through a structured, therapy-supported treatment model.","length":380,"tagName":"p"},{"type":"text","content":"“Initiating patient dosing is an important step forward for our clinical program and, more importantly, for the patients we aim to support,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “This study is designed to better understand both the safety and therapeutic potential of a 25mg dose of psilocybin in individuals facing significant emotional distress alongside serious illness. As we advance this work, we remain focused ...